Rosuvastatin

نویسندگان

چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Rosuvastatin Calcium

Pharmacology: Rosuvastatin selectively and competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the production of mevalonate, a cholesterol precursor. Rosuvastatin has high activity in, uptake into, and selectivity for the liver, the target organ. It enhances uptake and catabolism of LDL by increasing hepatic LDL receptor levels. It also inhibits the hepatic VLDL synthesis, red...

متن کامل

Rosuvastatin-warfarin drug interaction.

we estimate that there are more than 100000 patients presently on statin treatment, and that about 10% of these patients will also be on long-term warfarin therapy. I believe your Editorial was correct in highlighting the issue of safety, and to suggest that “physicians must tell their patients the truth about rosuvastatin”. However, I would add that physicians themselves should be informed of ...

متن کامل

Rosuvastatin-Induced Thrombocytopenic Purpura

Many medications can cause thrombocytopenic purpura, including some hypolipidemic agents. This is the fi rst case report of thrombocytopenic purpura due to the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, rosuvastatin. A 57-year-old Asian man developed multiple petechiae and purpura one month after receiving rosuvastatin in a dosage of 20 mg/day. When the drug was stopped and the ...

متن کامل

Current Perspectives on rosuvastatin

Rosuvastatin is one of the most potent statins available for reducing circulating low-density lipoprotein cholesterol (LDL-C) levels, which enables more high-risk patients to achieve their lipid goals. Its favorable balance of effects on atherogenic and protective lipoproteins and its pleiotropic effects, including anti-inflammatory and antioxidant effects and improvement in endothelial dysfunc...

متن کامل

Rosuvastatin and chronic hepatitis C

The prospective randomized clinical trial of Malaguarnera and colleagues, published in the current issue of Hepatitis Monthly, investigates the potential role of a commercially available HMG Co-A reductase agent—rosuvastatin (Crestor, Astra Zeneca)—in combination with non-pegylated interferon and ribavirin in the treatment of chronic hepatitis C (HCV). HMG Co-A reductase agents, commonly referr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: pharma-kritik

سال: 2007

ISSN: 1010-5409

DOI: 10.37667/pk.2006.33